Health economics - What the nephrologists should know

Nephrology Dialysis Transplantation

Volumn 20, Issue , 2005, Pages 1038-1041

  Palmer, Andrew J ^a  

^a IQVIA   (United States)

Author keywords

Cost effectiveness; Costs; Health economics; Modelling; Nephrology; Thresholds; Willingness to pay

Indexed keywords

BETA INTERFERON; IRBESARTAN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; CANCER SCREENING; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETIC NEPHROPATHY; DRUG COST; DRUG EFFICACY; EDITORIAL; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LIFE EXPECTANCY; LUNG CANCER; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; META ANALYSIS; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ECONOMICS; NEPHROLOGY; NOTE; OUTCOME ASSESSMENT; PHARMACOECONOMICS; PRACTICE GUIDELINE; PROBABILITY; STATISTICAL MODEL; UNITED STATES;

COST-BENEFIT ANALYSIS; ECONOMICS, MEDICAL; ECONOMICS, PHARMACEUTICAL; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; NEPHROLOGY; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 20844448245     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh824     Document Type: Editorial

References (10)

1. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 5 - working with Markov processes. Med Decis Making 1997; 17: 152-159
2. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479-500
3. Palmer AJ, Roze S, Valentine WJ et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004; 20 [8 Suppl]: 5-26
4. Palmer AJ, Tucker DMD, Valentine WJ, Roze S, Gabriel S, Cordonnier DJ. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant 2005, in press
5. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
6. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value in Health 2004; 7: 518-528
7. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 2003; 289: 313-322
8. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452
9. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995; 10: 321-330
10. Churchill DN, Lemon BC, Torrance GW. A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis and hospital hemodialysis. Medical Decision Making 1984; 4: 489-500